Impact of Aorto-Iliac Occlusive Disease Treatment on Blood Pressure
Recruiting · NCT07070583 · Interventional (participants receive a specific treatment) · Lead sponsor: Rijnstate Hospital
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
Hypertension is a major risk factor for a variety of cardiovascular diseases. When hypertension results from increased vascular resistance due to a narrowing of the descending aorta, it can be effectively treated with stenting. More recently, evidence suggest that stenting in more distal parts of the arterial vascular bed is also associated with a reduction in blood pressure. The investigators hypothesize that stenting of occlusions more distal of the descending aorta decreases the central blood pressure and afterload as reflected by NT-proBNP (N-terminal pro-Brain Natriuretic Peptide), a biomarker of intracardiac pressures and predictor of heart failure events. The goal of this pilot study is to prospectively investigate changes in blood pressure after stent placement in the aorto-iliac region.
Who can take part
Inclusion criteria
- Age ≥18 years
- Singed informed consent
- Chronic occlusion in the infrarenal aorta and/or one or both common iliac arteries
- Total lesion length of ≥30mm
- Clinical indication for treatment of the pathology (Chronic limb threatening ischemia or disabling intermittent claudication not responding to supervised exercise training)
Exclusion criteria
- Patient is unable to understand the study requirements and/ or is unwilling to adhere to the follow-up
- Juxtarenal pathology (\<2cm below the lowest renal artery)
- Acute occlusion of the target area (Acute Leriche Syndrome)
- Embolic disease
Where it is running
1 location listed.
- Rijnstate - Arnhem, Netherlands